1 / 4

Global Fondaparinux Market Share, Trends & Forecast to 2020-2026

Global Fondaparinux Market Size, Share & Trends Analysis Report, By Product Type (Branded and Generics) and Forecast, 2020-2026<br>

rishabh3210
Download Presentation

Global Fondaparinux Market Share, Trends & Forecast to 2020-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research Global Fondaparinux Market, Size, Share, Analysis Report & Forecast to 2026 Market: Request https://www.omrglobal.com/request-sample/fondaparinux-market a Free Sample of our Report on Fondaparinux Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

  2. The global fondaparinux market is estimated to grow at a CAGR of nearly 7.5% during the forecast period. Significant rise in the prevalence of arthritis is primarily driving the global fondaparinux market. As per the Centers for Disease Control and Prevention (CDC), by 2040, the number of adults aged 18 years and over in the US with doctor-diagnosed arthritis is estimated to rise 49% to 78.4 million (25.9% of the estimated total US adult population), compared to 54.4 million adults in 2013–2015. Additionally, as per the Versus Arthritis, in UK, musculoskeletal conditions including arthritis and back pain affected nearly 18.8 million people in 2017. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/fondaparinux-market Osteoarthritis is the most common form of arthritis that are affecting millions of people globally. Globally, over 200 million women suffer from osteoporosis. 1 in 3 postmenopausal women has osteoporosis, which increases with age. Therefore, increasing prevalence of geriatric population is also a major cause for the rising incidences of osteoarthritis. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age of 65, increased from 1 in 11 in 2019. In 2019, 703 million people were aged 65 years or over globally, which is expected to double to 1.5 billion in 2050. A https://www.omrglobal.com/industry-reports/fondaparinux-market Full Report of Global Fondaparinux Market is Available at: Osteoporosis commonly affects joints in hips, knees, spine, and hands, which results in the increasing number of hip and knee replacements. As per the Canadian Institute for Health Information (CIHI), in 2017-2018, 70,502 knee replacements and 58,492 hip replacements were performed in Canada. This shows a rise of 17.0% and 17.4%, respectively, over the last 5 years. According to the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR), there were a total of 242,629 cases registered to NJR during 2016/2017. It has shown a significant rise of over 20,000 joint replacement procedures than the previous year. This, in turn, is contributing to the adoption of fondaparinux to prevent deep vein thrombosis (blood clot) after the procedure. Fondaparinux is used for the treatment of severe blood clots in the lungs or legs. It is often utilizing with another blood thinner drugs (warfarin). If blood clots are untreated, it can travel to the brain, heart, or lungs, causing serious breathing problems, stroke, or heart attack. Fondaparinux is further used for the prevention of blood clots after some procedures with an increased risk of blood clots, including knee and hip replacements, abdominal surgery, and hip fracture. Fondaparinux works similarly like heparin that blocks the activity of some clotting substances in the blood. However, fondaparinux has a longer half-life than heparin and does not interact with platelets. This, in turn, is contributing to the growth of the global fondaparinux market. Global Fondaparinux Market- Segmentation By Product Type

  3. •Branded •Generics Global Fondaparinux Market– Segment by Region North America •United States •Canada Europe •Germany •UK •France •Spain •Italy •Rest of Europe Asia-Pacific •China •Japan •India •Rest of Asia-Pacific Rest of the World Company Profiles •Apicore LLC •Aurobindo Pharma Ltd. •Cadila Healthcare Ltd. (CHL) •Dr Reddy’s Laboratories Ltd. •GlaxoSmithKline plc •Italfarmaco S.p.A. •Mylan N.V. •Sandoz International GmbH •ScinoPharm Taiwan, Ltd.

  4. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/fondaparinux-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

More Related